ACON ACON
Company Profile ↓Company Overview
ACON (ACON) is a publicly traded company listed on with a market capitalization of $2.02M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $75.73K (+65.6% YoY); net profit $-7.23M.
- Trailing 12 Months Year-on-year growth — revenue +65.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.80% |
| 1 Year: | 65.62% |
Stock Price Performance
| 1 Year: | -66.29% |
| 6 Months: | -16.31% |
| 3 Months: | -26.25% |
| 1 Month: | -21.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 75.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.83K | 25.62K | 10.87K | 9.03K | 10.68K | 18.22K | 25.47K | 17.07K | 19.07K | 10.11K | 10.97K | 14.41K | - | 18.99K | 19.32K | 18.94K | 18.48K | 21.14K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.48K | 14.18K | 14.56K | 16.69K | 17.39K |
| Gross Profit | -4.74K | 5.32K | -5.22K | -7.71K | -3.57K | 1.19K | 8.02K | -2.23K | -493 | -9.36K | -12.32K | -6.92K | - | -4.49K | 5.14K | 4.39K | 1.79K | 3.75K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.49M | 1.74M | 1.84M | 1.99M | 2.99M |
| Operating Income | -460.54K | -626.62K | -797.25K | -773.10K | -2.21M | -1.63M | -1.18M | -1.41M | -1.16M | -1.28M | -1.14M | -1.30M | - | -1.49M | -1.74M | -1.83M | -1.99M | -2.99M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.44M | -1.55M | -1.65M | -1.83M | -2.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 271 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.04M | -1.60M | -1.71M | -1.89M | -2.85M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -517.86K | -465.84K | -2.95M | -936.09K | -3.55M | -1.63M | -1.18M | -1.46M | -998.01K | -2.40M | -1.24M | -1.37M | - | -2.04M | -1.60M | -1.71M | -1.89M | -2.85M |
| Diluted EPS | - | - | -3.58 | -1.35 | -0.47 | -0.20 | -2.39 | -2.83 | -1.87 | -3,985.22 | -1,362.83 | -1,321.49 | - | -9.32 | -2.75 | -2.93 | - | -1.34 |
| R&D Expense | 167.75K | 162.71K | 275.28K | 204.80K | 353.23K | 290.97K | 204.40K | 250.01K | 198.25K | 239.04K | 202.10K | 195.80K | - | 198.19K | 270.43K | 302.04K | - | 315.42K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 60.44K | 75.40K | 45.72K | 75.73K |
| Cost of Revenue | - | 65.30K | 75.73K | 84.66K | 68.90K |
| Gross Profit | - | -4.85K | -324 | -38.93K | 6.83K |
| Operating Expenses | - | 5.56M | 4.88M | 5.47M | 7.06M |
| Operating Income | - | -5.56M | -4.88M | -5.51M | -7.05M |
| EBITDA | - | -5.42M | -4.14M | -6.26M | -7.01M |
| Interest Expense | - | 1.51M | 608.29K | 535.47K | 0 |
| Pretax Income | - | -7.07M | -4.91M | -6.99M | -7.23M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -7.07M | -4.91M | -6.99M | -7.23M |
| Diluted EPS | - | -138,594.74 | -53,971.14 | -5,151.64 | -13.61 |
| R&D Expense | 787.85K | 1.07M | 873.34K | 888.77K | 1.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.91M | 2.46M | 2.12M | 13.67M |
| Current Assets | - | - | 1.70M | 1.29M | 824.28K | 12.40M |
| Cash & Equivalents | - | - | 1.47M | 1.02M | 453.66K | 12.02M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 18.57K | 13.27K | 18.33K | 29.68K |
| Total Liabilities | - | - | 688.67K | 3.19M | 1.15M | 837.29K |
| Current Liabilities | - | - | 688.67K | 3.19M | 1.15M | 837.29K |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | 2.00M | - | 1.13M | - | - |
| Total Equity | -7.08M | - | 2.23M | -728.00K | 970.06K | 12.84M |
| Shares Outstanding | - | - | 54 | 91 | 1.37K | 854.37K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.95M | -3.65M | -5.27M | -7.16M |
| Investing Cash Flow | - | -207.87K | -119.52K | -321.94K | -203.90K |
| Financing Cash Flow | - | 6.19M | 3.31M | 5.03M | 18.95M |
| Capital Expenditure | - | -208.87K | -119.52K | -321.94K | -203.90K |
| Free Cash Flow | - | -5.16M | -3.77M | -5.59M | -7.37M |
| Net Change in Cash | - | 1.03M | -451.74K | -567.41K | 11.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -8.0% | -0.4% | -85.2% | 9.0% |
| Operating Margin % | - | -9,202.5% | -6,468.0% | -12,057.2% | -9,312.5% |
| Net Margin % | - | -11,694.4% | -6,513.4% | -15,293.8% | -9,551.9% |
| ROE % | - | -317.6% | 674.6% | -720.9% | -56.4% |
| ROCE % | - | -249.9% | 669.9% | -568.3% | -54.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACON
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networksGoodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical researchAvai…
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
141% year-over-year scan volume growth in first half of 2026Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage fo…
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablationEarly findings from real-world evidence study demonstrate immense utility and ability of N…
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Texas Spine Care Center is a high-volume orthopedic spine practice with a philosophy of understanding the exact source of a patient's pain before recommending treatmentCLARITY is a prospective, randomized clinical trial designed to demonstr…
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) alg…
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan v…
ACON — Frequently Asked Questions
What is the current share price of ACON?
As of 2026-08-05 17:25 PDT, ACON trades at $2.36 on NASDAQ/NYSE. Its 52-week range is $2.02 to $9.69.
What is the market capitalisation of ACON?
ACON has a market capitalisation of $2.02M on NASDAQ/NYSE.
What is the P/E ratio of ACON?
ACON trades at a trailing price-to-earnings (P/E) ratio of -0.17. Its price-to-book (P/B) ratio is 0.16.
What is the return on equity (ROE) of ACON?
ACON has a return on equity (ROE) of -56.36%. Its return on capital employed (ROCE) is -54.95%.
Is ACON a good stock to buy?
This page provides a data-driven analysis of ACON, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.